A novel sustained-release formulation of insulin with dramatic reduction in initial rapid release

Takenaga, Mitsuko; Yamaguchi, Yoko; Kitagawa, Aki; Ogawa, Yasuaki; Mizushima, Yutaka; Igarashi, Rie

doi:10.1016/s0168-3659(01)00518-1

Cited by 60 publications

(27 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A limitation of the parenteral route for delivery of peptides and proteins is the extremely short half-lives of these drugs that demands repeated administration which is inconvenient to the patient (Mccarthy, 2004). To decrease injection frequency of basal insulin supply, several research groups have investigated the potential use of biodegradable polymers as a sustained-release carrier (Barichello et al, 1999;Choi and Kim, 2003;Kim et al, 2001;Takenaga et al, 2002). Previously, we found that the pegylated insulin forms PPRX with ␣-and ␥-CyDs in a similar manner as PEG does, and the resulting PPRX may be useful as one of sustained drug delivery techniques of pegylated insulin (Higashi et al, 2007(Higashi et al, , 2008(Higashi et al, , 2009).…”

Section: Introductionmentioning

confidence: 99%

Potential use of γ-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin

Hashim

Higashi

Anno

et al. 2010

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Potential use of γ-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin

Hashim

Higashi

Anno

et al. 2010

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…For this purpose, alginate, a naturally occurring biopolymer, offers advantages, including biocompatibility and relatively mild conditions required to produce an alginate matrix or particle (7). Extensive investigation has shown the efficacy of this release system when used to encapsulate protein agents such as insulin, erythropoietins, and chemokines (20,25,32). To further increase the efficacy of the capsular delivery, a novel recombinant form of the vitelline protein B (VpB) derived from the eggshell precursor of the parasite Fasciola hepatica was incorporated into the capsules (26).…”

mentioning

confidence: 99%

Immunization with a Single Dose of a Microencapsulated Brucella melitensis Mutant Enhances Protection against Wild-Type Challenge

et al. 2008

View full text Add to dashboard Cite

The development of safe and efficacious immunization systems to prevent brucellosis is needed to overcome the disadvantages of the currently licensed vaccine strains that restrict their use in humans. Alginate microspheres coated with a protein of the parasite Fasciola hepatica (vitelline protein B [VpB]) and containing live Brucella melitensis attenuated mutant vjbR::Tn5 (BMEII1116) were evaluated for vaccine efficacy and immunogenicity in mice. A single immunization dose in BALB/c mice with the encapsulated vjbR mutant improved protection against wild-type B. melitensis 16M challenge compared to the nonencapsulated vaccine strain (P < 0.05). The encapsulated mutant was also shown to induce a sustained elevation of Immunoglobulin G levels. Cytokine secretion from spleen cells of mice vaccinated with the encapsulated vjbR::Tn5 revealed elevated secretion of gamma interferon and interleukin-12, but no interleukin-4, suggesting an induction of a T helper 1 response reflecting the enhanced immunity associated with microencapsulation. Together, these results suggest that microencapsulation of live attenuated organisms offers the ability to increase the efficacy of vaccine candidates.Brucella, an obligate intracellular bacterium, is the causative agent of brucellosis, a zoonosis of nearly worldwide distribution (8). Among the six different Brucella species, Brucella melitensis, B. suis, and B. abortus are pathogenic and virulent not only for sheep, goats, swine, and cattle, respectively, but also for humans. Despite the availability of live vaccine strains for cattle (S19 and RB51) and small ruminants (Rev-1), these vaccines have several drawbacks, including interference with diagnosis, resistance to antibiotics, and residual virulence, that prevent the use of these vaccines in humans (4, 6, 28). Numerous attempts to develop safe and more effective vaccines, including the use of killed organisms, cell extracts, or recombinant proteins, has had limited success (18,22,27,28,33).In the absence of defined protective immunogens, the use of attenuated vaccine strains offers the best approach. As an alternative, we have investigated the ability to combine an attenuated live vaccine delivered in a controlled release vehicle. For this purpose, alginate, a naturally occurring biopolymer, offers advantages, including biocompatibility and relatively mild conditions required to produce an alginate matrix or particle (7). Extensive investigation has shown the efficacy of this release system when used to encapsulate protein agents such as insulin, erythropoietins, and chemokines (20,25,32). To further increase the efficacy of the capsular delivery, a novel recombinant form of the vitelline protein B (VpB) derived from the eggshell precursor of the parasite Fasciola hepatica was incorporated into the capsules (26). VpB possesses an unusual resistance to enzymatic and chemical breakdown that is expected to extend the time frame of erosion and release of the capsule content (34).Ongoing research in our laboratory has identified B. mel...

show abstract

“…Injectable microparticles from poly(D,L-lactide) (PLA) and poly(D,L-lactide-coglycolide) (PLGA) have been investigated for the delivery of insulin. [5][6][7][8][9] A high initial burst release was observed followed by a slow release over 1-2 weeks period. The release profile was affected by the addition of hydrophilic additives such as water and glycerol.…”

Section: Introductionmentioning

confidence: 94%

Controlled Delivery of Basal Insulin from Phase-Sensitive Polymeric Systems After Subcutaneous Administration: In Vitro Release, Stability, Biocompatibility, In Vivo Absorption, and Bioactivity of Insulin

Al-Tahami

Oak

Singh

2011

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

A novel sustained-release formulation of insulin with dramatic reduction in initial rapid release

Cited by 60 publications

References 25 publications

Potential use of γ-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin

Potential use of γ-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin

Immunization with a Single Dose of a Microencapsulated Brucella melitensis Mutant Enhances Protection against Wild-Type Challenge

Controlled Delivery of Basal Insulin from Phase-Sensitive Polymeric Systems After Subcutaneous Administration: In Vitro Release, Stability, Biocompatibility, In Vivo Absorption, and Bioactivity of Insulin

Contact Info

Product

Resources

About